Lonidamine: Difference between revisions
Created page with "{{Drugbox | Watchedfields = changed | verifiedrevid = 444558328 | IUPAC_name = 1-(2,4-dichlorobenzyl)-1''H''-indazole-3-carboxylic acid | image = Lonidamine.svg <!--Clinical..." |
No edit summary |
||
| Line 3: | Line 3: | ||
| verifiedrevid = 444558328 | | verifiedrevid = 444558328 | ||
| IUPAC_name = 1-(2,4-dichlorobenzyl)-1''H''-indazole-3-carboxylic acid | | IUPAC_name = 1-(2,4-dichlorobenzyl)-1''H''-indazole-3-carboxylic acid | ||
| image = Lonidamine. | | image = Lonidamine.png | ||
<!--Clinical data--> | <!--Clinical data--> | ||
| Line 47: | Line 47: | ||
| StdInChIKey = WDRYRZXSPDWGEB-UHFFFAOYSA-N | | StdInChIKey = WDRYRZXSPDWGEB-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Lonidamine''' is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic [[glycolysis]] in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound [[hexokinase]]. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.<ref name="pmid16892078">{{cite journal |author=Pelicano H, Martin DS, Xu RH, Huang P |title=Glycolysis inhibition for anticancer treatment |journal=Oncogene |volume=25 |issue=34 |pages=4633–4646 |date=August 2006 |pmid=16892078 |doi= 10.1038/sj.onc.1209597|url=http://www.kosen21.org/upload_repository2/community/01230411451209597a.pdf}}</ref> | '''Lonidamine''' is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic [[glycolysis]] in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound [[hexokinase]]. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.<ref name="pmid16892078">{{cite journal |author=Pelicano H, Martin DS, Xu RH, Huang P |title=Glycolysis inhibition for anticancer treatment |journal=Oncogene |volume=25 |issue=34 |pages=4633–4646 |date=August 2006 |pmid=16892078 |doi= 10.1038/sj.onc.1209597|url=http://www.kosen21.org/upload_repository2/community/01230411451209597a.pdf}}</ref> | ||
| Line 53: | Line 59: | ||
Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.<ref name="pmid19001677">{{cite journal |author=Prabhakara S, Kalia VK |title=Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine |journal=Indian J. Med. Res. |volume=128 |issue=2 |pages=140–8 |date=August 2008 |pmid=19001677 |doi= |url=http://www.icmr.nic.in/ijmr/2008/august/0808.pdf}}</ref> | Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.<ref name="pmid19001677">{{cite journal |author=Prabhakara S, Kalia VK |title=Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine |journal=Indian J. Med. Res. |volume=128 |issue=2 |pages=140–8 |date=August 2008 |pmid=19001677 |doi= |url=http://www.icmr.nic.in/ijmr/2008/august/0808.pdf}}</ref> | ||
A derivative of lonidamine, | A derivative of lonidamine, gamendazole, is in testing as a possible male contraceptive pill.<ref name=Tash>{{cite journal|last=Tash|first=Joseph|title=A Novel Potent Indazole Carboxylic Acid Derivative Blocks Spermatogenesis and Is Contraceptive in Rats after a Single Oral Dose|journal=Biology of Reproduction|date=July 2008|volume=78|issue=6|pages=1127–1138|doi=10.1095/biolreprod.106.057810|pmid=18218612|accessdate=31 July 2011}}</ref> | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Chemotherapeutic agents}} | {{Chemotherapeutic agents}} | ||
[[Category:Drug]] | |||
Revision as of 14:04, 13 April 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C15H10Cl2N2O2 |
| Molar mass | 321.158 g/mol |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
|
WikiDoc Resources for Lonidamine |
|
Articles |
|---|
|
Most recent articles on Lonidamine |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Lonidamine at Clinical Trials.gov Clinical Trials on Lonidamine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Lonidamine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Lonidamine Discussion groups on Lonidamine Patient Handouts on Lonidamine Directions to Hospitals Treating Lonidamine Risk calculators and risk factors for Lonidamine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Lonidamine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lonidamine is a derivative of indazole-3-carboxylic acid, which for a long time, has been known to inhibit aerobic glycolysis in cancer cells. It seems to enhance aerobic glycolysis in normal cells, but suppress glycolysis in cancer cells. This is most likely through the inhibition of the mitochondrially bound hexokinase. Later studies in Ehrlich ascites tumor cells showed that lonidamine inhibits both respiration and glycolysis leading to a decrease in cellular ATP.[1]
Clinical trials of lonidamine in combination with other anticancer agents for a variety of cancers has begun. This is due to its proven ability to inhibit energy metabolism in cancer cells, and to enhance the activity of anticancer agents.[1]
Lonidamine has been used in the treatment of brain tumours in combination with radiotherapy and temozolomide. Results showed that a combination of temozolomide and lonidamine at clinically achievable, low plasma concentrations, could inhibit tumour growth, and lonidamine could reduce the dose of temozolomide required for radiosensitization of brain tumours.[2]
A derivative of lonidamine, gamendazole, is in testing as a possible male contraceptive pill.[3]
References
- ↑ 1.0 1.1 Pelicano H, Martin DS, Xu RH, Huang P (August 2006). "Glycolysis inhibition for anticancer treatment" (PDF). Oncogene. 25 (34): 4633–4646. doi:10.1038/sj.onc.1209597. PMID 16892078.
- ↑ Prabhakara S, Kalia VK (August 2008). "Optimizing radiotherapy of brain tumours by a combination of temozolomide & lonidamine" (PDF). Indian J. Med. Res. 128 (2): 140–8. PMID 19001677.
- ↑ Tash, Joseph (July 2008). "A Novel Potent Indazole Carboxylic Acid Derivative Blocks Spermatogenesis and Is Contraceptive in Rats after a Single Oral Dose". Biology of Reproduction. 78 (6): 1127–1138. doi:10.1095/biolreprod.106.057810. PMID 18218612.
|access-date=requires|url=(help)
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages using citations with accessdate and no URL
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- Drug